TapImmune Inc. (TPIM.OB) recently announced that an independent third-party research group published an article in the Journal of Investigative Dermatology confirming that a TapImmune (TAP) vaccine should be considered as a therapy for treating Melanoma based cancer. The National Cancer Institute has forecasted that within the next five years cancer will be ranked as the number one cause of death by illness of Americans.

The company’s TAP vaccine against cancer helps the body move cancer makers to the surface of cells to allow a person’s body to detect and fight the cancerous cells. Initially developed at The University of British Columbia, the preclinical trials for melanoma and lung carcinoma in animal subjects show positive results. A 70% survival rate was achieved in test subjects when using the TAP vaccine therapy, while a 100% survival rate was achieved when the TAP was administered ex-vivo.

The TAP vaccine has also shown success

TapImmune, Inc. (OTCBB: TPIM) announced that their TAP incorporated vaccine for the treatment of cancer was recently reviewed by a third party research article in the Journal of Investigative Dermatology, which confirmed that the company’s vaccine should be considered as a therapy for cancer.

The article, entitled, “Restoration of the Expression of Transporters Associate with Antigen Processing in Human Malignant Melanoma Increases Tumor-Specific Immunity,” was published in advance online on April 3, 2008. TapImmune is a biotechnology company that specializes in the development of immunotherapeutics for cancer and vaccines for infectious diseases, and the company’s stock rose 37.10% in Monday’s trading.

The company’s promising TAP vaccine performs a key step in moving characteristic markers called antigens to the surfaces of cells. TAP, which stands for Transporters with Antigen Processing, are proteins responsible for supplying tumor-associated antigens (markers) and viral antigens to the surface of infected cells. Without